APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

FLT3 Antagonists

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global FLT3 Antagonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 173992270327 December 2025191 pages

Choose your research edition.

Industry ResearchFLT3 Antagonists Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal FLT3 Antagonists Industry Growth and Trends Forecast to 2032119 pages · $3,450 USDMarket StructureGlobal FLT3 Antagonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal FLT3 Antagonists Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal FLT3 Antagonists Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

The global FLT3 Antagonists market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for FLT3 Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for FLT3 Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for FLT3 Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for FLT3 Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of FLT3 Antagonists include Astellas Pharma, Bayer, Cipla, Daiichi Sankyo, Glenmark Pharmaceuticals, Lupin Pharma, Mylan, Natco Pharma and Novartis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global FLT3 Antagonists market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of FLT3 Antagonists and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents FLT3 Antagonists sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the FLT3 Antagonists market size, projected growth trends, production technologies, key applications, and end-use industries.

FLT3 Antagonists Segment by Company

Astellas Pharma

Bayer

Cipla

Daiichi Sankyo

Glenmark Pharmaceuticals

Lupin Pharma

Mylan

Natco Pharma

Novartis

Pfizer

Takeda Pharmaceuticals

Teva

Zydus

Hunan Kelun Pharmaceutical

Hansoh Pharma

Qilu Pharmaceutical

CSPC Pharmaceutical

FLT3 Antagonists Segment by Type

Gilteritinib

Quizartinib

Midostaurin

Sunitinib

Sorafenib

Other

FLT3 Antagonists Segment by Application

Systemic Mastocytosis

Gastrointestinal Stromal Tumors

Renal Cell Carcinoma

Acute Myeloid Leukemia

Hepatocellular Carcinoma

Other

FLT3 Antagonists Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global FLT3 Antagonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of FLT3 Antagonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of FLT3 Antagonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the FLT3 Antagonists market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of FLT3 Antagonists manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of FLT3 Antagonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of FLT3 Antagonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. FLT3 Antagonists Industry Trends Table 2. FLT3 Antagonists Industry Drivers Table 3. FLT3 Antagonists Industry Opportunities and Challenges Table 4. FLT3 Antagonists Industry Restraints Table 5. Global FLT3 Antagonists Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global FLT3 Antagonists Revenue Market Share by Manufacturers (2021-2026) Table 7. Global FLT3 Antagonists Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global FLT3 Antagonists Sales Market Share by Manufacturers Table 9. Global FLT3 Antagonists Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global FLT3 Antagonists Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global FLT3 Antagonists Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global FLT3 Antagonists Manufacturers, Product Type & Application Table 13. Global FLT3 Antagonists Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global FLT3 Antagonists by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Gilteritinib Table 17. Major Manufacturers of Quizartinib Table 18. Major Manufacturers of Midostaurin Table 19. Major Manufacturers of Sunitinib Table 20. Major Manufacturers of Sorafenib Table 21. Major Manufacturers of Other Table 22. Global FLT3 Antagonists Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global FLT3 Antagonists Sales by Type (2021-2026) & (K Units) Table 24. Global FLT3 Antagonists Sales by Type (2027-2032) & (K Units) Table 25. Global FLT3 Antagonists Sales Market Share by Type (2021-2026) Table 26. Global FLT3 Antagonists Sales Market Share by Type (2027-2032) Table 27. Global FLT3 Antagonists Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 28. Global FLT3 Antagonists Revenue by Type (2021-2026) & (K Units) Table 29. Global FLT3 Antagonists Revenue by Type (2027-2032) & (K Units) Table 30. Global FLT3 Antagonists Revenue Market Share by Type (2021-2026) Table 31. Global FLT3 Antagonists Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Systemic Mastocytosis Table 33. Major Manufacturers of Gastrointestinal Stromal Tumors Table 34. Major Manufacturers of Renal Cell Carcinoma Table 35. Major Manufacturers of Acute Myeloid Leukemia Table 36. Major Manufacturers of Hepatocellular Carcinoma Table 37. Major Manufacturers of Other Table 38. Global FLT3 Antagonists Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global FLT3 Antagonists Sales by Application (2021-2026) & (K Units) Table 40. Global FLT3 Antagonists Sales by Application (2027-2032) & (K Units) Table 41. Global FLT3 Antagonists Sales Market Share by Application (2021-2026) Table 42. Global FLT3 Antagonists Sales Market Share by Application (2027-2032) Table 43. Global FLT3 Antagonists Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 44. Global FLT3 Antagonists Revenue by Application (2021-2026) & (K Units) Table 45. Global FLT3 Antagonists Revenue by Application (2027-2032) & (K Units) Table 46. Global FLT3 Antagonists Revenue Market Share by Application (2021-2026) Table 47. Global FLT3 Antagonists Revenue Market Share by Application (2027-2032) Table 48. Global FLT3 Antagonists Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 49. Global FLT3 Antagonists Sales by Region (2021-2026) & (K Units) Table 50. Global FLT3 Antagonists Sales Market Share by Region (2021-2026) Table 51. Global FLT3 Antagonists Sales Forecasted by Region (2027-2032) & (K Units) Table 52. Global FLT3 Antagonists Sales Forecasted Market Share by Region (2027-2032) Table 53. North America FLT3 Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. North America FLT3 Antagonists Sales by Country (2021-2026) & (K Units) Table 55. North America FLT3 Antagonists Sales by Country (2027-2032) & (K Units) Table 56. Europe FLT3 Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Europe FLT3 Antagonists Sales by Country (2021-2026) & (K Units) Table 58. Europe FLT3 Antagonists Sales by Country (2027-2032) & (K Units) Table 59. Asia Pacific FLT3 Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 60. Asia Pacific FLT3 Antagonists Sales by Country (2021-2026) & (K Units) Table 61. Asia Pacific FLT3 Antagonists Sales by Country (2027-2032) & (K Units) Table 62. South America, Middle East and Africa FLT3 Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 63. South America, Middle East and Africa FLT3 Antagonists Sales by Country (2021-2026) & (K Units) Table 64. South America, Middle East and Africa FLT3 Antagonists Sales by Country (2027-2032) & (K Units) Table 65. Global FLT3 Antagonists Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 66. Global FLT3 Antagonists Revenue by Region (2021-2026) & (US$ Million) Table 67. Global FLT3 Antagonists Revenue by Region (2027-2032) & (US$ Million) Table 68. Global FLT3 Antagonists Revenue Market Share by Region (2021-2026) Table 69. Global FLT3 Antagonists Revenue Market Share by Region (2027-2032) Table 70. Astellas Pharma Company Information Table 71. Astellas Pharma Business Overview Table 72. Astellas Pharma FLT3 Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Astellas Pharma FLT3 Antagonists Product Portfolio Table 74. Astellas Pharma Recent Development Table 75. Bayer Company Information Table 76. Bayer Business Overview Table 77. Bayer FLT3 Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Bayer FLT3 Antagonists Product Portfolio Table 79. Bayer Recent Development Table 80. Cipla Company Information Table 81. Cipla Business Overview Table 82. Cipla FLT3 Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Cipla FLT3 Antagonists Product Portfolio Table 84. Cipla Recent Development Table 85. Daiichi Sankyo Company Information Table 86. Daiichi Sankyo Business Overview Table 87. Daiichi Sankyo FLT3 Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Daiichi Sankyo FLT3 Antagonists Product Portfolio Table 89. Daiichi Sankyo Recent Development Table 90. Glenmark Pharmaceuticals Company Information Table 91. Glenmark Pharmaceuticals Business Overview Table 92. Glenmark Pharmaceuticals FLT3 Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Glenmark Pharmaceuticals FLT3 Antagonists Product Portfolio Table 94. Glenmark Pharmaceuticals Recent Development Table 95. Lupin Pharma Company Information Table 96. Lupin Pharma Business Overview Table 97. Lupin Pharma FLT3 Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Lupin Pharma FLT3 Antagonists Product Portfolio Table 99. Lupin Pharma Recent Development Table 100. Mylan Company Information Table 101. Mylan Business Overview Table 102. Mylan FLT3 Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Mylan FLT3 Antagonists Product Portfolio Table 104. Mylan Recent Development Table 105. Natco Pharma Company Information Table 106. Natco Pharma Business Overview Table 107. Natco Pharma FLT3 Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Natco Pharma FLT3 Antagonists Product Portfolio Table 109. Natco Pharma Recent Development Table 110. Novartis Company Information Table 111. Novartis Business Overview Table 112. Novartis FLT3 Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Novartis FLT3 Antagonists Product Portfolio Table 114. Novartis Recent Development Table 115. Pfizer Company Information Table 116. Pfizer Business Overview Table 117. Pfizer FLT3 Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Pfizer FLT3 Antagonists Product Portfolio Table 119. Pfizer Recent Development Table 120. Takeda Pharmaceuticals Company Information Table 121. Takeda Pharmaceuticals Business Overview Table 122. Takeda Pharmaceuticals FLT3 Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Takeda Pharmaceuticals FLT3 Antagonists Product Portfolio Table 124. Takeda Pharmaceuticals Recent Development Table 125. Teva Company Information Table 126. Teva Business Overview Table 127. Teva FLT3 Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Teva FLT3 Antagonists Product Portfolio Table 129. Teva Recent Development Table 130. Zydus Company Information Table 131. Zydus Business Overview Table 132. Zydus FLT3 Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. Zydus FLT3 Antagonists Product Portfolio Table 134. Zydus Recent Development Table 135. Hunan Kelun Pharmaceutical Company Information Table 136. Hunan Kelun Pharmaceutical Business Overview Table 137. Hunan Kelun Pharmaceutical FLT3 Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 138. Hunan Kelun Pharmaceutical FLT3 Antagonists Product Portfolio Table 139. Hunan Kelun Pharmaceutical Recent Development Table 140. Hansoh Pharma Company Information Table 141. Hansoh Pharma Business Overview Table 142. Hansoh Pharma FLT3 Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 143. Hansoh Pharma FLT3 Antagonists Product Portfolio Table 144. Hansoh Pharma Recent Development Table 145. Qilu Pharmaceutical Company Information Table 146. Qilu Pharmaceutical Business Overview Table 147. Qilu Pharmaceutical FLT3 Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 148. Qilu Pharmaceutical FLT3 Antagonists Product Portfolio Table 149. Qilu Pharmaceutical Recent Development Table 150. CSPC Pharmaceutical Company Information Table 151. CSPC Pharmaceutical Business Overview Table 152. CSPC Pharmaceutical FLT3 Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 153. CSPC Pharmaceutical FLT3 Antagonists Product Portfolio Table 154. CSPC Pharmaceutical Recent Development Table 155. Key Raw Materials Table 156. Raw Materials Key Suppliers Table 157. FLT3 Antagonists Distributors List Table 158. FLT3 Antagonists Customers List Table 159. Research Programs/Design for This Report Table 160. Authors List of This Report Table 161. Secondary Sources Table 162. Primary Sources List of Figures Figure 1. FLT3 Antagonists Product Image Figure 2. Global FLT3 Antagonists Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global FLT3 Antagonists Market Size (2021-2032) & (US$ Million) Figure 4. Global FLT3 Antagonists Sales (2021-2032) & (K Units) Figure 5. Global FLT3 Antagonists Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 FLT3 Antagonists Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Gilteritinib Image Figure 9. Quizartinib Image Figure 10. Midostaurin Image Figure 11. Sunitinib Image Figure 12. Sorafenib Image Figure 13. Other Image Figure 14. Global FLT3 Antagonists Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global FLT3 Antagonists Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global FLT3 Antagonists Sales Market Share by Type (2021-2032) Figure 17. Global FLT3 Antagonists Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 18. Global FLT3 Antagonists Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global FLT3 Antagonists Revenue Market Share by Type (2021-2032) Figure 20. Systemic Mastocytosis Image Figure 21. Gastrointestinal Stromal Tumors Image Figure 22. Renal Cell Carcinoma Image Figure 23. Acute Myeloid Leukemia Image Figure 24. Hepatocellular Carcinoma Image Figure 25. Other Image Figure 26. Global FLT3 Antagonists Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 27. Global FLT3 Antagonists Sales Market Share 2021 VS 2025 VS 2032 Figure 28. Global FLT3 Antagonists Sales Market Share by Application (2021-2032) Figure 29. Global FLT3 Antagonists Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 30. Global FLT3 Antagonists Revenue Market Share 2021 VS 2025 VS 2032 Figure 31. Global FLT3 Antagonists Revenue Market Share by Application (2021-2032) Figure 32. North America FLT3 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 33. North America FLT3 Antagonists Sales Market Share by Country (2021-2032) Figure 34. U.S. FLT3 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Canada FLT3 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Mexico FLT3 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Europe FLT3 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Europe FLT3 Antagonists Sales Market Share by Country (2021-2032) Figure 39. Germany FLT3 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 40. France FLT3 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 41. U.K. FLT3 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Italy FLT3 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Netherlands FLT3 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Asia Pacific FLT3 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Asia Pacific FLT3 Antagonists Sales Market Share by Country (2021-2032) Figure 46. China FLT3 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Japan FLT3 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Korea FLT3 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Southeast Asia FLT3 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 50. India FLT3 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Australia FLT3 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 52. South America, Middle East and Africa FLT3 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 53. South America, Middle East and Africa FLT3 Antagonists Sales Market Share by Country (2021-2032) Figure 54. Brazil FLT3 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 55. South Africa FLT3 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Saudi Arabia FLT3 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Turkey FLT3 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Argentina FLT3 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 59. UAE FLT3 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 60. Egypt FLT3 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 61. Chile FLT3 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 62. Global FLT3 Antagonists Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 63. Global FLT3 Antagonists Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 64. North America FLT3 Antagonists Revenue (2021-2032) & (US$ Million) Figure 65. North America FLT3 Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Europe FLT3 Antagonists Revenue (2021-2032) & (US$ Million) Figure 67. Europe FLT3 Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Asia-Pacific FLT3 Antagonists Revenue (2021-2032) & (US$ Million) Figure 69. Asia-Pacific FLT3 Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. South America, Middle East and Africa FLT3 Antagonists Revenue (2021-2032) & (US$ Million) Figure 71. South America, Middle East and Africa FLT3 Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 72. FLT3 Antagonists Value Chain Figure 73. Manufacturing Cost Structure Figure 74. FLT3 Antagonists Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Years Considered Figure 78. Research Process Figure 79. Key Executives Interviewed

Scope & coverage.

Types
  • Gilteritinib
  • Quizartinib
  • Midostaurin
  • Sunitinib
  • Sorafenib
  • Other
Applications
  • Systemic Mastocytosis
  • Gastrointestinal Stromal Tumors
  • Renal Cell Carcinoma
  • Acute Myeloid Leukemia
  • Hepatocellular Carcinoma
  • Other
Companies covered
  • Astellas Pharma
  • Bayer
  • Cipla
  • Daiichi Sankyo
  • Glenmark Pharmaceuticals
  • Lupin Pharma
  • Mylan
  • Natco Pharma
  • Novartis
  • Pfizer
  • Takeda Pharmaceuticals
  • Teva
  • Zydus
  • Hunan Kelun Pharmaceutical
  • Hansoh Pharma
  • Qilu Pharmaceutical
  • CSPC Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global FLT3 Antagonists Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global FLT3 Antagonists Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global FLT3 Antagonists Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global FLT3 Antagonists Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global FLT3 Antagonists Market Dynamics
  1. 2.1 FLT3 Antagonists Industry Trends
  2. 2.2 FLT3 Antagonists Industry Drivers
  3. 2.3 FLT3 Antagonists Industry Opportunities and Challenges
  4. 2.4 FLT3 Antagonists Industry Restraints
3 FLT3 Antagonists Market by Manufacturers
  1. 3.1 Global FLT3 Antagonists Revenue by Manufacturers (2021-2026)
  2. 3.2 Global FLT3 Antagonists Sales by Manufacturers (2021-2026)
  3. 3.3 Global FLT3 Antagonists Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global FLT3 Antagonists Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global FLT3 Antagonists Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global FLT3 Antagonists Manufacturers, Product Type & Application
  7. 3.7 Global FLT3 Antagonists Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global FLT3 Antagonists Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 FLT3 Antagonists Players Market Share by Revenue in 2025
  11. 3.8.3 2025 FLT3 Antagonists Tier 1, Tier 2, and Tier 3
4 FLT3 Antagonists Market by Type
  1. 4.1 FLT3 Antagonists Type Introduction
  2. 4.1.1 Gilteritinib
  3. 4.1.2 Quizartinib
  4. 4.1.3 Midostaurin
  5. 4.1.4 Sunitinib
  6. 4.1.5 Sorafenib
  7. 4.1.6 Other
  8. 4.2 Global FLT3 Antagonists Sales by Type
  9. 4.2.1 Global FLT3 Antagonists Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global FLT3 Antagonists Sales by Type (2021-2032)
  11. 4.2.3 Global FLT3 Antagonists Sales Market Share by Type (2021-2032)
  12. 4.3 Global FLT3 Antagonists Revenue by Type
  13. 4.3.1 Global FLT3 Antagonists Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global FLT3 Antagonists Revenue by Type (2021-2032)
  15. 4.3.3 Global FLT3 Antagonists Revenue Market Share by Type (2021-2032)
5 FLT3 Antagonists Market by Application
  1. 5.1 FLT3 Antagonists Application Introduction
  2. 5.1.1 Systemic Mastocytosis
  3. 5.1.2 Gastrointestinal Stromal Tumors
  4. 5.1.3 Renal Cell Carcinoma
  5. 5.1.4 Acute Myeloid Leukemia
  6. 5.1.5 Hepatocellular Carcinoma
  7. 5.1.6 Other
  8. 5.2 Global FLT3 Antagonists Sales by Application
  9. 5.2.1 Global FLT3 Antagonists Sales by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global FLT3 Antagonists Sales by Application (2021-2032)
  11. 5.2.3 Global FLT3 Antagonists Sales Market Share by Application (2021-2032)
  12. 5.3 Global FLT3 Antagonists Revenue by Application
  13. 5.3.1 Global FLT3 Antagonists Revenue by Application (2021 VS 2025 VS 2032)
  14. 5.3.2 Global FLT3 Antagonists Revenue by Application (2021-2032)
  15. 5.3.3 Global FLT3 Antagonists Revenue Market Share by Application (2021-2032)
6 Global FLT3 Antagonists Sales by Region
  1. 6.1 Global FLT3 Antagonists Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global FLT3 Antagonists Sales by Region (2021-2032)
  3. 6.2.1 Global FLT3 Antagonists Sales by Region (2021-2026)
  4. 6.2.2 Global FLT3 Antagonists Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America FLT3 Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America FLT3 Antagonists Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe FLT3 Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe FLT3 Antagonists Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific FLT3 Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific FLT3 Antagonists Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa FLT3 Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa FLT3 Antagonists Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global FLT3 Antagonists Revenue by Region
  1. 7.1 Global FLT3 Antagonists Revenue by Region
  2. 7.1.1 Global FLT3 Antagonists Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global FLT3 Antagonists Revenue by Region (2021-2026)
  4. 7.1.3 Global FLT3 Antagonists Revenue by Region (2027-2032)
  5. 7.1.4 Global FLT3 Antagonists Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America FLT3 Antagonists Revenue (2021-2032)
  8. 7.2.2 North America FLT3 Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe FLT3 Antagonists Revenue (2021-2032)
  11. 7.3.2 Europe FLT3 Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific FLT3 Antagonists Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific FLT3 Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa FLT3 Antagonists Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa FLT3 Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Astellas Pharma
  2. 8.1.1 Astellas Pharma Company Information
  3. 8.1.2 Astellas Pharma Business Overview
  4. 8.1.3 Astellas Pharma FLT3 Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Astellas Pharma FLT3 Antagonists Product Portfolio
  6. 8.1.5 Astellas Pharma Recent Developments
  7. 8.2 Bayer
  8. 8.2.1 Bayer Company Information
  9. 8.2.2 Bayer Business Overview
  10. 8.2.3 Bayer FLT3 Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bayer FLT3 Antagonists Product Portfolio
  12. 8.2.5 Bayer Recent Developments
  13. 8.3 Cipla
  14. 8.3.1 Cipla Company Information
  15. 8.3.2 Cipla Business Overview
  16. 8.3.3 Cipla FLT3 Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Cipla FLT3 Antagonists Product Portfolio
  18. 8.3.5 Cipla Recent Developments
  19. 8.4 Daiichi Sankyo
  20. 8.4.1 Daiichi Sankyo Company Information
  21. 8.4.2 Daiichi Sankyo Business Overview
  22. 8.4.3 Daiichi Sankyo FLT3 Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Daiichi Sankyo FLT3 Antagonists Product Portfolio
  24. 8.4.5 Daiichi Sankyo Recent Developments
  25. 8.5 Glenmark Pharmaceuticals
  26. 8.5.1 Glenmark Pharmaceuticals Company Information
  27. 8.5.2 Glenmark Pharmaceuticals Business Overview
  28. 8.5.3 Glenmark Pharmaceuticals FLT3 Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Glenmark Pharmaceuticals FLT3 Antagonists Product Portfolio
  30. 8.5.5 Glenmark Pharmaceuticals Recent Developments
  31. 8.6 Lupin Pharma
  32. 8.6.1 Lupin Pharma Company Information
  33. 8.6.2 Lupin Pharma Business Overview
  34. 8.6.3 Lupin Pharma FLT3 Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Lupin Pharma FLT3 Antagonists Product Portfolio
  36. 8.6.5 Lupin Pharma Recent Developments
  37. 8.7 Mylan
  38. 8.7.1 Mylan Company Information
  39. 8.7.2 Mylan Business Overview
  40. 8.7.3 Mylan FLT3 Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Mylan FLT3 Antagonists Product Portfolio
  42. 8.7.5 Mylan Recent Developments
  43. 8.8 Natco Pharma
  44. 8.8.1 Natco Pharma Company Information
  45. 8.8.2 Natco Pharma Business Overview
  46. 8.8.3 Natco Pharma FLT3 Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Natco Pharma FLT3 Antagonists Product Portfolio
  48. 8.8.5 Natco Pharma Recent Developments
  49. 8.9 Novartis
  50. 8.9.1 Novartis Company Information
  51. 8.9.2 Novartis Business Overview
  52. 8.9.3 Novartis FLT3 Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Novartis FLT3 Antagonists Product Portfolio
  54. 8.9.5 Novartis Recent Developments
  55. 8.10 Pfizer
  56. 8.10.1 Pfizer Company Information
  57. 8.10.2 Pfizer Business Overview
  58. 8.10.3 Pfizer FLT3 Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Pfizer FLT3 Antagonists Product Portfolio
  60. 8.10.5 Pfizer Recent Developments
  61. 8.11 Takeda Pharmaceuticals
  62. 8.11.1 Takeda Pharmaceuticals Company Information
  63. 8.11.2 Takeda Pharmaceuticals Business Overview
  64. 8.11.3 Takeda Pharmaceuticals FLT3 Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Takeda Pharmaceuticals FLT3 Antagonists Product Portfolio
  66. 8.11.5 Takeda Pharmaceuticals Recent Developments
  67. 8.12 Teva
  68. 8.12.1 Teva Company Information
  69. 8.12.2 Teva Business Overview
  70. 8.12.3 Teva FLT3 Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Teva FLT3 Antagonists Product Portfolio
  72. 8.12.5 Teva Recent Developments
  73. 8.13 Zydus
  74. 8.13.1 Zydus Company Information
  75. 8.13.2 Zydus Business Overview
  76. 8.13.3 Zydus FLT3 Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Zydus FLT3 Antagonists Product Portfolio
  78. 8.13.5 Zydus Recent Developments
  79. 8.14 Hunan Kelun Pharmaceutical
  80. 8.14.1 Hunan Kelun Pharmaceutical Company Information
  81. 8.14.2 Hunan Kelun Pharmaceutical Business Overview
  82. 8.14.3 Hunan Kelun Pharmaceutical FLT3 Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Hunan Kelun Pharmaceutical FLT3 Antagonists Product Portfolio
  84. 8.14.5 Hunan Kelun Pharmaceutical Recent Developments
  85. 8.15 Hansoh Pharma
  86. 8.15.1 Hansoh Pharma Company Information
  87. 8.15.2 Hansoh Pharma Business Overview
  88. 8.15.3 Hansoh Pharma FLT3 Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Hansoh Pharma FLT3 Antagonists Product Portfolio
  90. 8.15.5 Hansoh Pharma Recent Developments
  91. 8.16 Qilu Pharmaceutical
  92. 8.16.1 Qilu Pharmaceutical Company Information
  93. 8.16.2 Qilu Pharmaceutical Business Overview
  94. 8.16.3 Qilu Pharmaceutical FLT3 Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Qilu Pharmaceutical FLT3 Antagonists Product Portfolio
  96. 8.16.5 Qilu Pharmaceutical Recent Developments
  97. 8.17 CSPC Pharmaceutical
  98. 8.17.1 CSPC Pharmaceutical Company Information
  99. 8.17.2 CSPC Pharmaceutical Business Overview
  100. 8.17.3 CSPC Pharmaceutical FLT3 Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 CSPC Pharmaceutical FLT3 Antagonists Product Portfolio
  102. 8.17.5 CSPC Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 FLT3 Antagonists Value Chain Analysis
  2. 9.1.1 FLT3 Antagonists Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 FLT3 Antagonists Production Mode & Process
  6. 9.2 FLT3 Antagonists Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 FLT3 Antagonists Distributors
  9. 9.2.3 FLT3 Antagonists Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst